Manuel Grossmann
Founding Partner @ Amino Collective
Berlin, Germany
Manuel Grossmann is a seed investor at Amino Collective in Berlin focused on Health Care and Software. Manuel Grossmann Founding Partner at Amino Collective VC. He attended Columbia Business School.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 5%
Last updated:
For AI agents: llms.txt
Industries Manuel Grossmann invests in
Stages Manuel Grossmann invests in
Countries Manuel Grossmann invests in
Round sizes
Round size
- Seed
- $2.4M–$15M
- Pre-Seed
- $125k–$3.3M
- Series A
- $12M–$27M
Investment Focus
Industry
- Health Care 8 (36%)
- Software 3 (14%)
- Biotechnology 3 (14%)
- Medical 2 (9%)
- Wellness 2 (9%)
Stage
- Seed 9 (41%)
- Series A 5 (23%)
- Pre-Seed 4 (18%)
- Funding Round 1 (5%)
Country
- Germany 5 (23%)
- United States 2 (9%)
- United Kingdom 2 (9%)
- Spain 1 (5%)
- Austria 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Calibre
|
Calibre uses causal AI in conjunction with clinical expertise to help people understand what is truly influencing their health and how to modify it. | $3.3M / Pre-Seed / Apr 22, 2026 | |
Anima
|
Anima's online patient triage speeds up the clinical workflow 10x and allows providers to deliver the right care for patients within 24 hours.Millions of patients with serious problems are missed and die every year because there isn’t adequate information flow between medical appointments. Patients submit their problems and requests onAnimainstead of waiting for an appointment, and Anima sends an actionable report to their provider with trends, risks and recommendations. | $12M / Series A / Mar 19, 2024 | |
Lindus
|
Lindus Health's mission is to accelerate research for the next generation of health companies. | $18M / Series A / Aug 16, 2023 | |
Kernal Biologics
|
Kernal creates mRNA therapies to cure diseases like COVID and cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. Kernal won three awards from Amgen and NASA. With roots at MIT, Harvard and Big Pharma, the team previously built a successful Biotech company and has deep expertise in mRNA space. | $25M / Series A / Jul 07, 2022 | |
|
Aware
|
Aware is a mobile app for evaluating health data and for researching chronic diseases. | $15M / Seed / Jun 27, 2022 | |
Molecule
|
Molecule is a software platform used to decentralise intellectual property development in the biotech industry. The company was founded in 2020 by Paul Kohlhaas and Tyler Golato and is headquartered in Schaffhausen, Switzerland. | $12.7M / Seed / Jun 13, 2022 | |
|
Kernal Biologics
|
Kernal creates mRNA therapies to cure diseases like COVID and cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. Kernal won three awards from Amgen and NASA. With roots at MIT, Harvard and Big Pharma, the team previously built a successful Biotech company and has deep expertise in mRNA space. | $20.1M / Feb 25, 2022 | |
Nostos Genomics
|
At Nostos Genomics, we partner with genetic testing labs to give more people with genetic diseases a clear and fast diagnosis. To achieve this, we developed a platform that leverages a unique combination of machine learning and synthetic biology. | $5.7M / Seed / Feb 03, 2022 | |
Kenbi
|
Kenbi is a nurse centric outpatient care company. | $26.6M / Series A / Dec 16, 2021 | |
|
Aware
|
Aware is a mobile app for evaluating health data and for researching chronic diseases. | Seed / Dec 01, 2021 | |
| See all 22 investments → | |||
Co-Investors
Entrepreneurs First
6 deals together
Entrepreneurs First
3 deals together
42CAP
2 deals together
Acequia Capital (AceCap)
2 deals together
Atlantic
2 deals together
Calm/Storm VC
2 deals together
About Amino Collective
Amino Collective is an institutional venture capital firm investing at seed stage in health and bio companies. They help bring life-changing ideas to life by backing, connecting, and advancing our collective of entrepreneurs and scientists. The firm intends to invest in the sectors of biology, biotech, health tech, science, digital health, lifescience, and synthetic biology.
Amino Collective Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Manuel Grossmann
Founding Partner
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Manuel Grossmann invest in?
Manuel Grossmann invests primarily in Health Care, Software and Biotechnology startups, most often at Seed and Series A stage. Most of the 22 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Manuel Grossmann's check size?
Manuel Grossmann typically joins rounds of $2.4M–$15M at Seed, $125k–$3.3M at Pre-Seed and $12M–$27M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Manuel Grossmann participates in.
When did Manuel Grossmann last invest?
The most recent investment recorded for Manuel Grossmann closed in Apr 2026. Shizune tracks 22 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
